Myocardial infarction and viral triggers: what do we know by now?

被引:9
|
作者
Caldeira, Daniel [1 ,2 ,3 ,4 ]
Nogueira-Garcia, Beatriz [1 ,2 ]
机构
[1] Univ Lisbon, Ctr Cardiovasc Univ Lisboa CCUL, Fac Med, CAML, Lisbon, Portugal
[2] Hosp Univ Santa Maria CHULN, Cardiol Dept, Lisbon, Portugal
[3] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal
[4] Univ Lisbon, Fac Med, Ctr Estudos Med Baseada Evidencia CEMBE, Lisbon, Portugal
关键词
Acute coronary syndrome; Influenza vaccine; COVID-19; Troponin; Myocardial injury; HERPES-SIMPLEX-VIRUS; CARDIOVASCULAR-DISEASE; INFLUENZA VACCINATION; ACUTE INFECTION; RISK; CYTOMEGALOVIRUS; BURDEN; DEATH;
D O I
10.1093/eurheartjsupp/suac122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocardial infarction (MI) is an acute clinical manifestation ischaemic heart disease, which is the leading cause of death worldwide. Infections also have an important burden worldwide, with lower respiratory infections being the worldwide leading cause of death due to communicable diseases. The relationship of MI with viral respiratory infections (including influenza and SARS-CoV-2) as a trigger has been well documented with significant associations. These infections can lead to Type 1 MI, where inflammation and vascular dysfunction, as well as the increased prothrombotic environment lead to atherothrombosis. Type 2 MI may also occur due to an imbalance of oxygen/blood supply and myocardial demand (hypoxaemia, fever, and tachycardia). The data from randomized controlled trials showing a potential benefit of influenza vaccination in coronary artery disease patients should not be ignored. This can be considered a further argument for the association of viral infections (influenza in particular) and MI.
引用
收藏
页码:A12 / A16
页数:5
相关论文
共 50 条
  • [1] HYPERSEXUALITY: WHAT DO WE KNOW BY NOW?
    Azevedo, P. A.
    Ferreira Carvalho, R. F. C.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : S392 - S393
  • [2] Transfusion triggers in the ICU: what do we know?
    Pinto, Vasanthi
    Abayadeera, Anuja
    SRI LANKAN JOURNAL OF ANAESTHESIOLOGY, 2014, 22 (02): : 42 - 43
  • [3] NOW THAT WE KNOW YOUTH, WHAT WILL WE DO ABOUT IT
    ESTY, JC
    PHI DELTA KAPPAN, 1976, 57 (06) : 418 - 419
  • [4] Swift-Certain-Fair What Do We Know Now, and What Do We Need to Know?
    Kleiman, Mark A. R.
    Criminology & Public Policy, 2016, 15 (04) : 1185 - 1193
  • [5] Editorial: Myocardial fibrosis: What we know now
    Kania, Gabriela
    Lindner, Diana
    Zuppinger, Christian
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 9
  • [6] What do we know about retention now?
    Richardson, Lorna
    EDINBURGH LAW REVIEW, 2018, 22 (03) : 387 - 393
  • [7] The risk of viral transmission in feed: What do we know, what do we do?
    Dee, Scott A.
    Niederwerder, Megan C.
    Patterson, Gil
    Cochrane, Roger
    Jones, Cassie
    Diel, Diego
    Brockhoff, Egan
    Nelson, Eric
    Spronk, Gordon
    Sundberg, Paul
    TRANSBOUNDARY AND EMERGING DISEASES, 2020, 67 (06) : 2365 - 2371
  • [8] Religion and democratisation: what do we now know?
    Haynes, Jeffrey
    JOURNAL OF RELIGIOUS AND POLITICAL PRACTICE, 2016, 2 (02) : 267 - 272
  • [9] Anthocyanins: What do we know until now?
    Giampieri, Francesca
    Cianciosi, Danila
    Alvarez-Suarez, Jose M.
    Quiles, Jose L.
    Forbes-Hernandez, Tamara Y.
    Navarro-Hortal, Maria D.
    Machi, Michele
    Pali Casanova, Ramon del Jesus
    Martinez Espinosa, Julio Cesar
    Chen, Xiumin
    Di Zhang
    Bai, Weibin
    Tian Lingmin
    Mezzetti, Bruno
    Battino, Maurizio
    Diaz, Yasmany Armas
    JOURNAL OF BERRY RESEARCH, 2023, 13 (01) : 1 - 6
  • [10] The Dawn of Mitophagy: What Do We Know by Now?
    Belousov, Dmitrii M.
    Mikhaylenko, Elizaveta, V
    Somasundaram, Siva G.
    Kirkland, Cecil E.
    Aliev, Gjumrakch
    CURRENT NEUROPHARMACOLOGY, 2021, 19 (02) : 170 - 192